Altheia Science develops curative cell and gene therapies specifically targeting autoimmune diseases, utilizing advanced techniques to modify patient cells for therapeutic purposes. This approach aims to provide long-term relief and potential cures for conditions that currently lack effective treatments.
Funding
$19.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Autoimmune diseases lack effective long-term treatments, often requiring continuous management of symptoms rather than offering a potential cure. Current therapies may not address the underlying causes of these conditions, leaving patients with persistent health challenges.
Solution
Altheia Science is developing cell and gene therapies focused on providing curative treatments for autoimmune diseases. The company uses advanced techniques to modify patient cells, aiming to correct the immune system's dysfunction and provide lasting relief. This approach seeks to address the root causes of autoimmune disorders, offering the potential for long-term remission or a cure, rather than just managing symptoms. By targeting the underlying mechanisms of these diseases, Altheia Science aims to transform the lives of patients who currently lack effective treatment options.
Target Audience
The primary target audience includes individuals suffering from autoimmune diseases and healthcare providers seeking innovative and curative treatment options.
Features
- Development of cell therapies targeting specific autoimmune diseases.
- Utilization of gene editing technologies to modify patient cells.
- Focus on achieving long-term remission or cure of autoimmune conditions.